The results suggest that targeting p38 MAPK may reduce IL-6 but not other important chemokines such as MCP-1/CCL2, and that targeting STAT signaling may reduce MCP-1/CCL2 in airway smooth muscle in asthma. Here, IL6 is linked to asthma.